Drug side effects
acamprosate Side Effects
The reactions most often reported to the FDA for acamprosate (also sold as Campral), with demographics, serious outcomes, and reporting trends.
Data updated 2026-05-15
- 299
- FAERS reports
Data from the FDA Adverse Event Reporting System (FAERS), 2006 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.
The most commonly reported side effects of acamprosate come from 299 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.
This page analyzes 299 reports to the FDA Adverse Event Reporting System (FAERS) for acamprosate (Campral): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.
Total Reports
299
Reports Mentioning Death
25
8.4% of reports — not proof the medicine caused the death
Hospitalizations
144
48.2% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 25 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| TOXICITY TO VARIOUS AGENTS | 8 |
| COMPLETED SUICIDE | 6 |
| DEATH | 5 |
| INTERSTITIAL LUNG DISEASE | 3 |
| CARDIAC ARREST | 2 |
| GASTROINTESTINAL HAEMORRHAGE | 2 |
| ASPHYXIA | 1 |
| CARDIO-RESPIRATORY ARREST | 1 |
| CIRCULATORY COLLAPSE | 1 |
| DRUG TOXICITY | 1 |
| INTENTIONAL OVERDOSE | 1 |
| MULTIPLE DRUG OVERDOSE INTENTIONAL | 1 |
| SUICIDE ATTEMPT | 1 |
| TRANSPLANT | 1 |
Reactions in Hospitalization Reports
Top reactions in 144 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| ACUTE KIDNEY INJURY | 12 |
| CONDITION AGGRAVATED | 11 |
| COMA | 10 |
| CYTOLYTIC HEPATITIS | 9 |
| DRUG ABUSE | 9 |
| HYPOGLYCAEMIA | 9 |
| HYPOTENSION | 9 |
| OVERDOSE | 9 |
| ATRIOVENTRICULAR BLOCK | 8 |
| BRADYCARDIA | 8 |
| ALCOHOL WITHDRAWAL SYNDROME | 7 |
| DEPRESSION | 7 |
| DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS | 7 |
| FATIGUE | 7 |
| HEPATIC CYTOLYSIS | 7 |
| RESPIRATORY DISTRESS | 7 |
| TACHYCARDIA | 7 |
| AGITATION | 6 |
| ASTHENIA | 6 |
| CHOLESTASIS | 6 |
Nearby, Related Medications
What the FAERS Data Reveals About acamprosate Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 299 voluntary reports linked to acamprosate and its brand equivalents (Campral), spanning 2006 through 2025. Of those, 25 (8.4%) listed death as an outcome and 144 (48.2%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 40% were female and 60% male; age distribution skews toward 45-64, with 113 reports in that bracket. The single most reported reaction is hypotension with 14 submissions, followed by asthenia and condition aggravated.
How to read these numbers
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.
Drugs With a Similar FAERS Report Volume
Other medications with a total FDA adverse-event report count closest to acamprosate's 299.
Read our methodology - how this data is sourced, computed, and verified.